Non-Small Cell Lung Cancer — Adjuvant Therapy for Completely Resected Stages I-IIIA

Publication Date: February 17, 2022

Key Points

Key Points

  • Lung cancers are the leading cause of cancer-related deaths for men and women throughout the world. In the United States, approximately 237,000 new cases of lung cancer are expected in 2022, and more than 130,000 individuals are expected to die as a result of the disease.a
  • Five-year survival rates range from 67% for T1N0 disease to 23% for patients with in T1-3N2 disease.
  • Adenocarcinomas and squamous cell lung cancers, which are the focus of this guideline, comprise approximately 82% of all lung cancers.b
a American Cancer Society: Key Statistics for Lung Cancer 2022. https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html
b American Cancer Society: Cancer Facts and Figures, 2022. Atlanta, GA, American Cancer Society, 2022.

Treatment

...Treatment...

...Adjuvant Systemic...

...juvant chemotherapy is NOT recommended. (EB/PC...

...T ≤ 4 cm, N0M0). Adjuvant osimertinib is...

...latin-based chemotherapy and/or atezolizumab are N...

...IA, IIB, and IIIA. Adjuvant cisplatin...


...Adjuvant Radiatio...

...age IA/B and IIA/B: Adjuvant radiation therapy...

...IIIA (N2): Adjuvant radiation therapy...